{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:31:50Z","timestamp":1785429110804,"version":"3.56.0"},"reference-count":55,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004913","name":"University of Palermo","doi-asserted-by":"publisher","award":["PJ_GEST_FFR_2025"],"award-info":[{"award-number":["PJ_GEST_FFR_2025"]}],"id":[{"id":"10.13039\/501100004913","id-type":"DOI","asserted-by":"publisher"}]},{"award":["PJ_GEST_FFR_2025"],"award-info":[{"award-number":["PJ_GEST_FFR_2025"]}],"id":[{"id":"https:\/\/ror.org\/044k9ta02","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Background\/Objectives: Medullary thyroid carcinoma (MTC) is a rare and aggressive endocrine malignancy frequently associated with RET alterations and dysregulation of RET-associated signaling pathways. In previous studies, first-generation nitro-substituted thieno[3,2-c]quinolines 1 showed promising antiproliferative activity in TT(RETC634R) cells, while subsequent imidazole-based optimization generated second-generation derivatives 2 with broad-spectrum antiproliferative activity in the NCI-60 human tumor cell line panel. Since thyroid cancer models are not included in the NCI-60 platform, the present study aimed to evaluate the antiproliferative potential of these optimized derivatives in clinically relevant MTC cellular models. Methods: Imidazole-functionalized thieno[3,2-c]quinoline derivatives (2a\u2013j) were evaluated against TT(RETC634R) and MZ-CRC-1(RETM918T) cells. The most active compounds were further characterized through induced fit docking (IFD), MM-GBSA calculations, and molecular dynamics (MD) simulations on representative molecular targets. In silico ADME\/Toxicity profiling was also performed to assess their developability. Results: Several derivatives exhibited potent activity in both MTC cell models, with multiple compounds achieving submicromolar potency. Compounds 2b and 2g emerged as the most active derivatives in TT(RETC634R) cells, whereas compounds 2d and 2i displayed the most favorable profile in the aggressive MZ-CRC-1(RETM918T) model, thereby extending the biological applicability of the scaffold to an additional clinically relevant RET-mutant context. Computational studies supported RET as the most plausible molecular target for all selected lead compounds, while favorable PI3K\u03b1 interaction profiles were predicted for selected derivatives, suggesting distinct target engagement profiles within the series. The most promising derivatives also exhibited an overall favorable predicted ADME\/Toxicity profile. Conclusions: The present findings support the success of imidazole-based optimization of the thieno[3,2-c]quinoline scaffold and identify thieno[3,2-c]quinolines 2 as promising lead structures for the future development of novel anti-MTC agents. Further biological and mechanistic investigations will be necessary to better clarify the molecular mechanisms underlying their antiproliferative activity and to guide future lead optimization studies.<\/jats:p>","DOI":"10.3390\/ph19071037","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T11:39:11Z","timestamp":1783078751000},"page":"1037","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Imidazole-Functionalized Thieno[3,2-c]Quinoline Hybrids in Aggressive Medullary Thyroid Cancer Cell Models: Biological Evaluation and in Silico Insights"],"prefix":"10.3390","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6510-1943","authenticated-orcid":false,"given":"Gabriele","family":"La Monica","sequence":"first","affiliation":[{"name":"Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche \u201cSTEBICEF\u201d, University of Palermo, 90123 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9283-4920","authenticated-orcid":false,"given":"Alessia","family":"Bono","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche \u201cSTEBICEF\u201d, University of Palermo, 90123 Palermo, Italy"},{"name":"Fondazione Umberto Veronesi (FUV), Via Solferino 19, 20121 Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-8281-3511","authenticated-orcid":false,"given":"Federica","family":"Alamia","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche \u201cSTEBICEF\u201d, University of Palermo, 90123 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1930-1754","authenticated-orcid":false,"given":"Dennis","family":"Tocco","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche \u201cSTEBICEF\u201d, University of Palermo, 90123 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6052-8438","authenticated-orcid":false,"given":"Giuseppe","family":"Pizzolanti","sequence":"additional","affiliation":[{"name":"Department of Health Promotion, Mother and Child Care, Internal Medicine and Medical Specialties (PROMISE), University of Palermo, 90127 Palermo, Italy"},{"name":"Advanced Technologies Network Center (ATEN Center), University of Palermo, 90128 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5116-6815","authenticated-orcid":false,"given":"Antonino","family":"Lauria","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche \u201cSTEBICEF\u201d, University of Palermo, 90123 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9560-1882","authenticated-orcid":false,"given":"Annamaria","family":"Martorana","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche \u201cSTEBICEF\u201d, University of Palermo, 90123 Palermo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1158\/1055-9965.EPI-21-1440","article-title":"Epidemiology of Thyroid Cancer","volume":"31","author":"Kitahara","year":"2022","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/S0140-6736(23)00020-X","article-title":"Thyroid Cancer","volume":"401","author":"Chen","year":"2023","journal-title":"Lancet"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41574-023-00920-6","article-title":"Genomic Alterations in Thyroid Cancer: Biological and Clinical Insights","volume":"20","author":"Landa","year":"2024","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"101655","DOI":"10.1016\/j.beem.2022.101655","article-title":"Medullary Thyroid Cancer\u2014An Update","volume":"37","author":"Fugazzola","year":"2023","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kaliszewski, K., Ludwig, M., Ludwig, B., Miku\u0142a, A., Greniuk, M., and Rudnicki, J. (2022). Update on the Diagnosis and Management of Medullary Thyroid Cancer: What Has Changed in Recent Years?. Cancers, 14.","DOI":"10.3390\/cancers14153643"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1210\/endrev\/bnad013","article-title":"Medullary Thyroid Cancer: Updates and Challenges","volume":"44","author":"Gild","year":"2023","journal-title":"Endocr. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Sahakian, N., Castinetti, F., and Romanet, P. (2023). Molecular Basis and Natural History of Medullary Thyroid Cancer: It Is (Almost) All in the RET. Cancers, 15.","DOI":"10.3390\/cancers15194865"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1038\/s41574-021-00470-9","article-title":"The Importance of the RET Gene in Thyroid Cancer and Therapeutic Implications","volume":"17","author":"Salvatore","year":"2021","journal-title":"Nat. Rev. Endocrinol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"17588359221101691","DOI":"10.1177\/17588359221101691","article-title":"RET Kinase Inhibitors for RET-Altered Thyroid Cancers","volume":"14","author":"Vodopivec","year":"2022","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"108948","DOI":"10.1016\/j.bioorg.2025.108948","article-title":"Overcoming Resistance in RET-Altered Cancers through Rational Inhibitor Design and Combination Therapies","volume":"165","author":"Wang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1021\/acs.jmedchem.3c02319","article-title":"Unraveling the Promise of RET Inhibitors in Precision Cancer Therapy by Targeting RET Mutations","volume":"67","author":"Wang","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s12020-014-0380-1","article-title":"PI3K\/Akt\/MTOR Signaling in Medullary Thyroid Cancer: A Promising Molecular Target for Cancer Therapy","volume":"48","author":"Manfredi","year":"2015","journal-title":"Endocrine"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.surg.2008.06.028","article-title":"The Phosphatidylinositol 3-Kinase\/Akt Signaling Pathway in Medullary Thyroid Cancer","volume":"144","author":"Pitt","year":"2008","journal-title":"Surgery"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"20420188251336091","DOI":"10.1177\/20420188251336091","article-title":"Systemic Therapies for Medullary Thyroid Carcinoma: State of the Art","volume":"16","author":"Califano","year":"2025","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Regua, A.T., Najjar, M., and Lo, H.-W. (2022). RET Signaling Pathway and RET Inhibitors in Human Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.932353"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Kooijman, J.J., van Riel, W.E., Dylus, J., Prinsen, M.B.W., Grobben, Y., de Bitter, T.J.J., van Doornmalen, A.M., Melis, J.J.T.M., Uitdehaag, J.C.M., and Narumi, Y. (2022). Comparative Kinase and Cancer Cell Panel Profiling of Kinase Inhibitors Approved for Clinical Use from 2018 to 2020. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.953013"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"100521","DOI":"10.1016\/j.coemr.2024.100521","article-title":"Insights into Highly Selective RET Inhibitors in Medullary Thyroid Cancer","volume":"35","author":"Matrone","year":"2024","journal-title":"Curr. Opin. Endocr. Metab. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"764","DOI":"10.2174\/1570193X20666230601151439","article-title":"Chemistry and Biological Activity of Thieno[3,4-b]Quinoline, Thieno[3,4-c]Quinolone, Thieno[3,2-g]Quinoline and Thieno[2,3-g]Quinoline Derivatives: A Review (Part IX)","volume":"21","author":"Abdelgawad","year":"2024","journal-title":"Mini-Rev. Org. Chem."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1080\/10426507.2021.2012176","article-title":"Synthesis and Chemical Reactions of Thieno[3,2-c]Quinolines from Arylamine Derivatives, Part (V): A Review","volume":"197","author":"Abdelgawad","year":"2022","journal-title":"Phosphorus Sulfur Silicon Relat. Elem."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1002\/ajoc.202000427","article-title":"Recent Advances in the Synthesis of Thienoquinolines (Quinoline-fused Heterocycle)","volume":"9","author":"Teja","year":"2020","journal-title":"Asian J. Org. Chem."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/10426507.2025.2611022","article-title":"Exploring the Anticancer Potential of Thienoquinoline Derivatives: A Comprehensive Review","volume":"201","author":"Dave","year":"2026","journal-title":"Phosphorus Sulfur Silicon Relat. Elem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"34640","DOI":"10.1021\/acsomega.3c03578","article-title":"Design and Synthesis of Novel Thieno[3,2-c]Quinoline Compounds with Antiproliferative Activity on RET-Dependent Medullary Thyroid Cancer Cells","volume":"8","author":"Pizzolanti","year":"2023","journal-title":"ACS Omega"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"29118","DOI":"10.1021\/acsomega.6c02681","article-title":"Imidazole-Functionalized Thieno[3,2-c]Quinolines as Promising Antiproliferative Agents: Design, Synthesis, NCI-60 Screening, and Computational Analysis","volume":"11","author":"Bono","year":"2026","journal-title":"ACS Omega"},{"key":"ref_24","unstructured":"Harwood, S., Ketcham, J.M., Ivetac, A., Smith, C.R., Marx, M.A., Pearson, K.E., and Lawson, J.D. (2024). Substituted Tricyclic Compounds. (International Publication No. WO 2024\/163707 A1)."},{"key":"ref_25","unstructured":"Reddy, E.P., and Reddy, M.V.R. (2015). 3-aminothieno[3,2-c]Quinoline Derivatives, Methods of Preparation and Uses. (U.S. Patent Application No. 14\/384,254)."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3141","DOI":"10.1158\/1078-0432.CCR-18-2953","article-title":"Comprehensive Genetic Characterization of Human Thyroid Cancer Cell Lines: A Validated Panel for Preclinical Studies","volume":"25","author":"Landa","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/1878-0261.12070","article-title":"Synergistic Activity of Everolimus and 5-aza-2\u2032-deoxycytidine in Medullary Thyroid Carcinoma Cell Lines","volume":"11","author":"Vitale","year":"2017","journal-title":"Mol. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2244","DOI":"10.1111\/jcmm.12612","article-title":"Synergistic Antitumour Activity of RAF265 and ZSTK474 on Human TT Medullary Thyroid Cancer Cells","volume":"19","author":"Bertazza","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Carra, S., Gaudenzi, G., Dicitore, A., Saronni, D., Cantone, M.C., Plebani, A., Ghilardi, A., Borghi, M.O., Hofland, L.J., and Persani, L. (2021). Vandetanib versus Cabozantinib in Medullary Thyroid Carcinoma: A Focus on Anti-Angiogenic Effects in Zebrafish Model. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22063031"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"10428","DOI":"10.1074\/jbc.RA119.007682","article-title":"Structural Basis of Resistance of Mutant RET Protein-Tyrosine Kinase to Its Inhibitors Nintedanib and Vandetanib","volume":"294","author":"Terzyan","year":"2019","journal-title":"J. Biol. Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.molcel.2014.01.015","article-title":"Oncogenic RET Kinase Domain Mutations Perturb the Autophosphorylation Trajectory by Enhancing Substrate Presentation In Trans","volume":"53","author":"Barnouin","year":"2014","journal-title":"Mol. Cell"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"16589","DOI":"10.1021\/acs.jmedchem.2c01422","article-title":"Discovery of GDC-0077 (Inavolisib), a Highly Selective Inhibitor and Degrader of Mutant PI3K\u03b1","volume":"65","author":"Hanan","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0022-1759(83)90303-4","article-title":"Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays","volume":"65","author":"Mosmann","year":"1983","journal-title":"J. Immunol. Methods"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Saronni, D., Gaudenzi, G., Dicitore, A., Carra, S., Cantone, M.C., Borghi, M.O., Barbieri, A., Mignani, L., Hofland, L.J., and Persani, L. (2022). Preclinical Evaluation of Novel Tyrosine-Kinase Inhibitors in Medullary Thyroid Cancer. Cancers, 14.","DOI":"10.3390\/cancers14184442"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/jnci\/djh184","article-title":"Cellular Effects and Antitumor Activity of RET Inhibitor RPI-1 on MEN2A-Associated Medullary Thyroid Carcinoma","volume":"96","author":"Cuccuru","year":"2004","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1158\/1078-0432.CCR-11-2700","article-title":"Activation of the MTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node Metastases","volume":"18","author":"Tamburrino","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s12020-015-0597-7","article-title":"The CAMP Analogs Have Potent Anti-Proliferative Effects on Medullary Thyroid Cancer Cell Lines","volume":"51","author":"Dicitore","year":"2016","journal-title":"Endocrine"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"Hong, S.-K., Starenki, D., Johnson, O.T., Gestwicki, J.E., and Park, J.-I. (2022). Analogs of the Heat Shock Protein 70 Inhibitor MKT-077 Suppress Medullary Thyroid Carcinoma Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23031063"},{"key":"ref_39","unstructured":"(LigPrep, 2025). LigPrep, Schr\u00f6dinger Release 2025\u20133."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1002\/jcc.20292","article-title":"Integrated Modeling Program, Applied Chemical Theory (IMPACT)","volume":"26","author":"Banks","year":"2005","journal-title":"J. Comput. Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1093\/nar\/28.1.235","article-title":"The Protein Data Bank","volume":"28","author":"Berman","year":"2000","journal-title":"Nucleic Acids Res."},{"key":"ref_42","unstructured":"(2026, June 01). RCSB PDB. Available online: https:\/\/www.Rcsb.Org."},{"key":"ref_43","unstructured":"(Protein Preparation Wizard, 2017). Protein Preparation Wizard, Prime."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10822-013-9644-8","article-title":"Protein and Ligand Preparation: Parameters, Protocols, and Influence on Virtual Screening Enrichments","volume":"27","author":"Adzhigirey","year":"2013","journal-title":"J. Comput. Aided. Mol. Des."},{"key":"ref_45","unstructured":"(Induced Fit Docking Protocol, 2017). Induced Fit Docking Protocol, Prime."},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Bono, A., La Monica, G., Alamia, F., Mingoia, F., Gentile, C., Peri, D., Lauria, A., and Martorana, A. (2023). In Silico Mixed Ligand\/Structure-Based Design of New CDK-1\/PARP-1 Dual Inhibitors as Anti-Breast Cancer Agents. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241813769"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"La Monica, G., Lauria, A., Bono, A., and Martorana, A. (2021). Off-Target-Based Design of Selective Hiv-1 Protease Inhibitors. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22116070"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.jmgm.2009.08.012","article-title":"Induced-Fit Docking Studies of the Active and Inactive States of Protein Tyrosine Kinases","volume":"28","author":"Zhong","year":"2009","journal-title":"J. Mol. Graph. Model."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1016\/j.jmgm.2008.09.002","article-title":"Induced-Fit Docking of Mometasone Furoate and Further Evidence for Glucocorticoid Receptor 17\u03b1 Pocket Flexibility","volume":"27","author":"Wang","year":"2008","journal-title":"J. Mol. Graph. Model."},{"key":"ref_50","unstructured":"(2017). Prime, Schr\u00f6dinger Release 2017-2."},{"key":"ref_51","unstructured":"(Desmond Molecular Dynamics System, 2023). Desmond Molecular Dynamics System, Maestro-Desmond Interoperability Tools."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"42717","DOI":"10.1038\/srep42717","article-title":"SwissADME: A Free Web Tool to Evaluate Pharmacokinetics, Drug-Likeness and Medicinal Chemistry Friendliness of Small Molecules","volume":"7","author":"Daina","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"W53","DOI":"10.1093\/nar\/gku401","article-title":"ProTox: A Web Server for the in Silico Prediction of Rodent Oral Toxicity","volume":"42","author":"Drwal","year":"2014","journal-title":"Nucleic Acids Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"W257","DOI":"10.1093\/nar\/gky318","article-title":"ProTox-II: A Webserver for the Prediction of Toxicity of Chemicals","volume":"46","author":"Banerjee","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"W513","DOI":"10.1093\/nar\/gkae303","article-title":"ProTox 3.0: A Webserver for the Prediction of Toxicity of Chemicals","volume":"52","author":"Banerjee","year":"2024","journal-title":"Nucleic Acids Res."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/7\/1037\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:06:31Z","timestamp":1783080391000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/7\/1037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":55,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["ph19071037"],"URL":"https:\/\/doi.org\/10.3390\/ph19071037","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]}}}